Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Holding LBPH?
Track your performance easily
LBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $40.48
Previous Close$29.31
Volume975.47K
Average Volume (3M)677.18K
Market Cap
$1.14B
Enterprise Value$839.13M
Total Cash (Recent Filing)$304.87M
Total Debt (Recent Filing)$3.86M
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
Oct 31, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding38,899,521
10 Day Avg. Volume602,826
30 Day Avg. Volume677,178
Standard Deviation0.48
R-Squared0.02
Alpha0.07
Financial Highlights & Ratios
Price to Book (P/B)3.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-12.59
Forecast
1Y Price Target
$64.14Price Target Upside92.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Longboard Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe great efficacy achieved by the placebo patients who switched over to bexicaserin in the OLE should help put to rest any remaining questions about whether any differences in baseline characteristics between arms contributing to the PACIFIC results.
Market PotentialBexicaserin will likely quickly takeover much of the existing Fintepla market, and then expand this market substantially.
Regulatory MilestonesBexicaserin received Breakthrough Therapy designation from FDA for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older.
Bears Say
Clinical TrialsInvestors have been focused on the titration scheme for bexicaserin and implications for dropout rate in Ph3 trials, given 11/43 participants randomized to bexicaserin in PACIFIC discontinued (8 of which occurred during the titration.
Market ReactionLBPH shares were down in Monday’s trading, against a backdrop of broader XBI weakness.
Stock ValuationThere is currently minimal credit in the stock for LP659.
---
Ownership Overview
1.35% Insiders
26.17% Mutual Funds
64.14% Other Institutional Investors
8.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Longboard Pharmaceuticals lowest stock price was $3.60 and its highest was $40.48 in the past 12 months.
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
Longboard Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 41 days.
How were Longboard Pharmaceuticals’s earnings last quarter?
Longboard Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.441 by -$0.119.
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate is -$0.58.
How many shares outstanding does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals has 34,290,020 shares outstanding.
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Longboard Pharmaceuticals reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.441. Following the earnings report the stock price went down -0.213%.
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is RA Capital Management. It holds Longboard Pharmaceuticals’s shares valued at 89M.
---
Longboard Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.14 (92.04% Upside)
$64.14 (92.04% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.6%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
381.28%
12-Months-Change
Fundamentals
Return on Equity
-36.71%
Trailing 12-Months
Asset Growth
372.50%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Earnings Call
Q2 2024
0:00 / 0:00
---
LBPH Stock 12 Month Forecast
Average Price Target
$64.14
▲(92.04% Upside)
Technical Analysis
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+41.04%
reiterated a buy rating 3 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +41.04% per trade.
---